Comparison Effect of Tenofovir and Entecavir in the Treatment of Chronic Hepatitis B
Objective:To compare the effect of Tenofovir and Entecavir in the treatment of chronic hepatitis B(CHB).Method:A prospective study was conducted on 82 patients with CHB who admitted to the Third People's Hospital of Yongzhou City from January 2021 to June 2023,the patients were divided into the control group and the observation group by random number table method,41 cases in each group.The control group was treated with Entecavir orally,and the observation group was treated with Tenofovir orally,two groups were treated for 6 months.The clinical efficacy,liver function indexes,inflammation indexes,liver fibrosis indexes,quality of life,HBV-DNA negative conversion rate and adverse reactions were compared between two groups.Result:The total effective rate of the observation group was higher than that of the control group,the levels of total bilirubin(TBIL),gamma-glutamyl transpeptidase(GGT),aspartate aminotransferase(AST),alanine aminotransferase(ALT),tumor necrosis factor-α(TNF-α),interleukin-17(IL-17),interleukin-22(IL-22),type Ⅳ collagen(Ⅳ-C),hyaluronic acid(HA)and laminin(LN)after treatment were lower than those of the control group,the physiological,psychological,social and environmental scores and HBV-DNA negative rate were higher than those of the control group,and the differences were statistically significant(P<0.05);but there was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:The effect of Tenofovir in the treatment of CHB is better than that of Entecavir,which can better inhibit HBV replication,accelerate HBV-DNA negative conversion,reduce liver damage,protect liver function,and is safe and reliable.
国家科技期刊平台
NSTL
万方数据
